Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human papillomavirus vaccine bivalent + tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This combination refers to the co-administration of the bivalent human papillomavirus (HPV) vaccine (Cervarix) and the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine (Boostrix). Developed by GSK, this regimen is designed to provide comprehensive protection against cervical cancer (caused by HPV types 16 and 18), tetanus, diphtheria, and pertussis in a single clinical visit, primarily targeting the adolescent population. Cervarix utilizes recombinant L1 capsid proteins that form virus-like particles (VLPs) and is formulated with the AS04 adjuvant system. Boostrix is a booster vaccine containing inactivated toxins (toxoids) and purified pertussis antigens adsorbed onto aluminum salts. Clinical studies, such as NCT00518674, have demonstrated that co-administration does not compromise the immunogenicity or safety profile of either vaccine compared to separate administrations, facilitating the integration of HPV vaccination into the existing adolescent immunization platform.
- Brand names
- CervarixBoostrix
- Other names
- HPV bivalent vaccine + Tdap vaccinehuman papillomavirus vaccine bivalent + TdapCervarix + Boostrix
02
Targets
TLR4 (Toll-like receptor 4)HPV16 (Human papillomavirus type 16)PRN (Pertactin)Diphtheria toxinFHA (Filamentous hemagglutinin)HPV18 L1
Beyond the preview
Go deeper on human papillomavirus vaccine bivalent + tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human papillomavirus vaccine bivalent + tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed.